— Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported earnings of $2.71 per share in the fourth-quarter 2019, vs. $2.60 per share expected.
— Total revenue rose 23% to $1.38 billion, vs. $1.31 billion expected. SOLIRIS net sales rose 11% to $3.94 billion.
— For FY20, Alexion expects revenues of $5.50 – $5.56 billion. Adjusted EPS is projected to be $10.65 to $10.85.
— ALXN stock gained 1.8% during pre-market hours immediately following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Earnings calendar for the week of Oct. 19
Undoubtedly the biggest event of the week was the launch of iPhone 12, the latest in Apple's smartphone series. Pre-orders for the standard model starts Friday, while the premium version
Walgreens Boots Alliance (WBA) to invest $1 billion in omnichannel capabilities next year
Shares of Walgreens Boots Alliance (NASDAQ: WBA) have dropped 36% since the beginning of the year, and the stock remained in red on Friday. The company reported its fourth quarter
BNY Mellon (BK) Earnings: Key financials and quarterly highlights
The Bank of New York Mellon Corporation (NYSE: BK) reported third quarter 2020 earnings results today. Total revenue of $3.8 billion dipped less than 1% versus last year. Net income
One thought on “Alexion Pharmaceuticals, Inc. (ALXN): Earnings Snapshot”
Comments are closed.